Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study

The Lancet Infectious Diseases

Volumn 17, Issue 1, 2017, Pages 68-77

  Chow, Eric P F ^a,b   Machalek, Dorothy A ^c,d   Tabrizi, Sepehr N ^c,d,e   Danielewski, Jennifer A ^c,d   Fehler, Glenda ^a   Bradshaw, Catriona S ^a,b   Garland, Suzanne M ^c,d,e   Chen, Marcus Y ^a,b   Fairley, Christopher K ^a,b  

^a MELBOURNE SEXUAL HEALTH CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d ROYAL WOMEN'S HOSPITAL   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADULT; AGE; ARTICLE; AUSTRALIA; AUSTRALIAN; BIRTHPLACE; COOK ISLANDS; ENGLAND; HETEROSEXUAL MALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 68; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NORTHERN IRELAND; OBSERVATIONAL STUDY; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCOTLAND; VACCINATION; WALES; YOUNG ADULT; ADOLESCENT; CHEMISTRY; CLASSIFICATION; FEMALE; GENOTYPE; IMMUNOLOGY; ISOLATION AND PURIFICATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVENTIVE HEALTH SERVICE; REPRODUCTIVE HEALTH; UTILIZATION; VIROLOGY;

ADOLESCENT; AUSTRALIA; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; IMMUNIZATION PROGRAMS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; REPRODUCTIVE HEALTH; RETROSPECTIVE STUDIES; VACCINATION; YOUNG ADULT;

EID: 84973562825     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30116-5     Document Type: Article

References (28)

1. 1 Kirby, T, Australia to be first country to vaccinate boys against HPV. Lancet Oncol, 13, 2012, e333.
2. 2 Chow, EP, Read, TR, Wigan, R, et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect 91 (2015), 214–219.
3. 3 Ali, H, Donovan, B, Wand, H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ, 346, 2013, f2032.
4. 4 Chow, EP, Danielewski, JA, Fehler, G, et al. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study. Lancet Infect Dis 15 (2015), 1314–1323.
5. 5 Tabrizi, SN, Brotherton, JM, Kaldor, JM, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis 14 (2014), 958–966.
6. 6 Read, TR, Hocking, JS, Chen, MY, Donovan, B, Bradshaw, CS, Fairley, CK, The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 87 (2011), 544–547.
7. 7 Tabrizi, SN, Brotherton, JM, Kaldor, JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 206 (2012), 1645–1651.
8. 8 Barbaro, B, Brotherton, JM, Assessing HPV vaccine coverage in Australia by geography and socioeconomic status: are we protecting those most at risk?. Aust N Z J Public Health 38 (2014), 419–423.
9. 9 Van de Velde, N, Boily, MC, Drolet, M, et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst 104 (2012), 1712–1723.
10. 10 Regan, DG, Philp, DJ, Hocking, JS, Law, MG, Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Sex Health 4 (2007), 147–163.
11. 11 US Food and Drug Administration. Gardasil 9. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm426445.htm (accessed July 9, 2015).
12. 12 Chow, EP, Fehler, G, Chen, MY, et al. Testing commercial sex workers for sexually transmitted infections in Victoria, Australia: an evaluation of the impact of reducing the frequency of testing. PLoS One, 9, 2014, e103081.
13. 13 Gamagedara, N, Hocking, JS, Law, M, et al. What are seasonal and meteorological factors are associated with the number of attendees at a sexual health service? An observational study between 2002–2012. Sex Transm Infect 90 (2014), 635–640.
14. 14 Mannion, PK, Fairley, CK, Fehler, G, et al. Trends in gonorrhoea positivity by nucleic acid amplification test versus culture among Australian heterosexual men with a low prevalence of gonorrhoea, 2007–2014. Sex Transm Infect, 2016, 10.1136/sextrans-2015-052246 published online Feb 17.
15. 15 Lim, MS, El-Hayek, C, Goller, JL, et al. Trends in chlamydia positivity among heterosexual patients from the Victorian Primary Care Network for Sentinel Surveillance, 2007–2011. Med J Aust 200 (2014), 166–169.
16. 16 Vodstrcil, LA, Fairley, CK, Fehler, G, et al. Trends in chlamydia and gonorrhea positivity among heterosexual men and men who have sex with men attending a large urban sexual health service in Australia, 2002–2009. BMC Infect Dis, 11, 2011, 158.
17. 17 Chow, EP, Fairley, CK, Assortative sexual mixing among heterosexual population in Australia: implications for herd protection in males from female human papillomavirus vaccination programme. Sex Health, 2016, 10.1071/SH15246 published online May 5.
18. 18 Bruni, L B-RL, Albero, G, Aldea, M, et al. ICO information centre on HPV and cancer (HPV, Centre). I. Human papillomavirus and related diseases in the world. Summary report 2015-12-23, 2015, ICO information centre on HPV and cancer (HPV Information Centre), Barcelona, Spain.
19. 19 Mesher, D, Panwar, K, Thomas, SL, Beddows, S, Soldan, K, Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study. BMJ Open, 6, 2016, e009915.
20. 20 Garland, SM, Molesworth, EG, Machalek, DA, Cornall, AM, Tabrizi, SN, How to best measure the effectiveness of male human papillomavirus vaccine programmes?. Clin Microbiol Infection 21 (2015), 834–841.
21. 21 Enerly, E, Olofsson, C, Nygard, M, Monitoring human papillomavirus prevalence in urine samples: a review. Clin Epidemiol 5 (2013), 67–79.
22. 22 Flores, R, Abalos, AT, Nielson, CM, Abrahamsen, M, Harris, RB, Giuliano, AR, Reliability of sample collection and laboratory testing for HPV detection in men. J Virol Methods 149 (2008), 136–143.
23. 23 Koene, F, Wolffs, P, Brink, A, et al. Comparison of urine samples and penile swabs for detection of human papillomavirus in HIV-negative Dutch men. Sex Transm Infect, 2016, 10.1136/sextrans-2015-052054 published online Feb 26.
24. 24 Hernandez, BY, Wilkens, LR, Zhu, X, et al. Circumcision and human papillomavirus infection in men: a site-specific comparison. J Infect Dis 197 (2008), 787–794.
25. 25 Giuliano, AR, Nielson, CM, Flores, R, et al. The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: the HPV detection in men study. J Infect Dis 196 (2007), 1146–1152.
26. 26 Zou, H, Tabrizi, SN, Grulich, AE, et al. Early acquisition of anogenital human papillomavirus among teenage men who have sex with men. J Infect Dis 209 (2014), 642–651.
27. 27 Homfray, V, Tanton, C, Miller, RF, et al. Male circumcision and STI acquisition in Britain: evidence from a national probability sample survey. PLoS One, 10, 2015, e0130396.
28. 28 Lu, PJ, Yankey, D, Jeyarajah, J, et al. HPV vaccination coverage of male adolescents in the United States. Pediatrics 136 (2015), 839–849.